These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8287239)

  • 21. Expanding clinical role of unique class III antiarrhythmic effects of sotalol.
    Singh BN
    Am J Cardiol; 1990 Jan; 65(2):84A-88A. PubMed ID: 2403738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolerance to the repolarization effects of rac-sotalol during long-term treatment.
    Padrini R; Gusella M; Al Bunni M; Piovan D; Zordan R; Magnolfi G; Maiolino P; Ferrari M
    Br J Clin Pharmacol; 1997 Nov; 44(5):463-70. PubMed ID: 9384463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rate dependence of sotalol-induced prolongation of ventricular repolarization during exercise in humans.
    Funck-Brentano C; Kibleur Y; Le Coz F; Poirier JM; Mallet A; Jaillon P
    Circulation; 1991 Feb; 83(2):536-45. PubMed ID: 1846784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concentration-dependent pharmacologic properties of sotalol.
    Wang T; Bergstrand RH; Thompson KA; Siddoway LA; Duff HJ; Woosley RL; Roden DM
    Am J Cardiol; 1986 May; 57(13):1160-5. PubMed ID: 3706170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol.
    Merot J; Charpentier F; Poirier JM; Coutris G; Weissenburger J
    Cardiovasc Res; 1999 Nov; 44(2):303-14. PubMed ID: 10690307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New antiarrhythmic drug in pediatric use: sotalol.
    Pfammatter JP; Paul T
    Pediatr Cardiol; 1997; 18(1):28-34. PubMed ID: 8960489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolving role of sotalol in the management of ventricular tachyarrhythmias.
    O'Callaghan PA; McGovern BA
    Am J Cardiol; 1996 Aug; 78(4A):54-60. PubMed ID: 8780329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of sotalol for life-threatening ventricular arrhythmias.
    Roden DM
    Am J Cardiol; 1993 Aug; 72(4):51A-55A. PubMed ID: 8346727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of sotalol and quinidine in a canine model of torsades de pointes: no increase in the QT-related proarrhythmic action of sotalol.
    Chézalviel-Guilbert F; Deplanne V; Davy JM; Poirier JM; Xia YZ; Cheymol G; Weissenburger J
    J Cardiovasc Electrophysiol; 1998 May; 9(5):498-507. PubMed ID: 9607458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is class III antiarrhythmic activity important?
    Singh BN
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():597-602. PubMed ID: 2275889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute and chronic effects of sotalol and propranolol on ventricular repolarization using constant-rate pacing.
    Creamer JE; Nathan AW; Shennan A; Camm AJ
    Am J Cardiol; 1986 May; 57(13):1092-6. PubMed ID: 3518383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of sotalol in patients with complex ventricular arrhythmias.
    Hohnloser SH; Zabel M; van de Loo A; Klingenheben T; Just H
    Int J Cardiol; 1992 Dec; 37(3):283-91. PubMed ID: 1281807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs.
    Kowey PR; Marinchak RA; Rials SJ; Bharucha D
    Am J Cardiol; 1997 Oct; 80(8A):16G-23G. PubMed ID: 9354408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evaluation of antiarrhythmic efficacy of sotalol in various doses in patients with ventricular tachyarrhythmias].
    Luczak D; Dabrowski R; Szwed H; Gasior Z; Stanke A; Jasek S; Skrabucha B; Matar A; Kowalik I
    Pol Merkur Lekarski; 1997 Feb; 2(8):122-5. PubMed ID: 9538657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
    Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
    J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects.
    Barbey JT; Sale ME; Woosley RL; Shi J; Melikian AP; Hinderling PH
    Clin Pharmacol Ther; 1999 Jul; 66(1):91-9. PubMed ID: 10430114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
    Lazzara R
    Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.